FIG 4.
Mucosal and plasma NCI05 and NCI09 levels in passively immunized animals. (A) Study design of passive immunization (NCI05 in red, NCI09 in blue) and 1:250 intrarectal SIVmac251 challenges (black arrows). (B and C) Concentrations of (B) NCI05 and (C) NCI09 measured in the plasma by ΔV1 gp120 ELISA during the SIVmac251 challenge phase. Colored arrows below the x axis indicate the times of passive immunization 4 days prior to each challenge. (D and E) ELISA detection of V2 MAb binding in the plasma of animals 1 week after the first passive immunization with NCI05 and NCI09 to (D) peptide 150 (biotin-GGG-LKSDKKIEYNETWYSRD) and (E) peptide 115 (biotin-GGG-GLKRDKTKEYN), respectively. (F and G) Mucosal concentrations of (F) NCI05 and (G) NCI09 measured by ΔV1 gp120 ELISA during the SIVmac251 challenge phase. (H) Geometric means of V2 MAbs measured in the rectal mucosa of the NCI05 and NCI09 groups. (I and J) Spearman rank correlation between the geometric mean of total mucosal IgG and mucosal (I) NCI05 and (J) NCI09. (K) Percent ADCC killing in plasma from passively immunized macaques mediated by macaque NKG2A+ NK effectors from the NCI05 and NCI09 groups. (L) Percent ADCC killing in plasma from passively immunized macaques mediated by human PBMC effectors. (M) Efferocytosis by CD14+ efferocytes in PBMCs collected prior to passive immunization from the NCI05 and NCI09 groups.